Chancen der onkoplastischen Brustrekonstruktion

Max Dieterich

  1. RKI: Robert-Koch-Institut: Evaluation of cancer incidence in germany (2007–2010). www.rki.de/DE/Home/homepage_node.html. (last accessed on 5 March 2015). 2015.
  2. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18(12):1927-1934.
  3. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF: Neoadjuvant therapy for breast cancer. J Surg Oncol 2010, 101(4):283-291.
  4. Clough KB, Lewis JS, Couturaud B, Fitoussi A, Nos C, Falcou MC: Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Ann Surg 2003, 237(1):26-34.
  5. Asgeirsson KS, Rasheed T, McCulley SJ, Macmillan RD: Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol 2005, 31(8):817-823.
  6. etit Y, Rietjens M: Deformities after conservative breast cancer treatment. In Noone RB, Low DW, eds. Plastic and Reconstructive Surgery of the Breast. Hamilton, Ontario: BC Decker, 1991, pp 455-466. 1991.
  7. Dieterich M, Dieterich H, Nestle-Krämling C, Gerber B: Certification of Breast Surgeons in Germany – AWO-gyn Curriculum in an International Comparison. Geburtsh Frauenheilk 2009, 69(11):987-991.
  8. Audretsch W, Rezai M, Kolotas C, et al.: Onco-plastic surgery: "target" volume reduction (BCT-mastopexy), lumpectomy reconstruction (BCT-reconstruction) and flap-supported operability in breast cancer. . Proceedings 2nd European Congress on Senology 1994:139-157.
  9. Slavin SA: Reconstruction of the breast conservation patient. In: Spear SL, editor. Surgery of the breast: principles and art. Philadelphia: LippincoteRaven Publishers; 1998, p. 221–38.
  10. Dieterich M, Dieterich H, Moch H, Rosso C: Re-excision Rates and Local Recurrence in Breast Cancer Patients Undergoing Breast Conserving Therapy. Geburtshilfe Frauenheilkd 2012, 72(11):1018-1023.
  11. Hernanz F, Regano S, Vega A, Gomez Fleitas M: Reduction mammaplasty: an advantageous option for breast conserving surgery in large-breasted patients. Surg Oncol 2010, 19(4):e95-e102.
  12. Dieterich H: State of the Art Onkoplastische Operationen. Süddeutsche Tagung für Gynäkologie und Geburtshilfe 2009.
  13. Danikas D, Theodorou SJ, Kokkalis G, Vasiou K, Kyriakopoulou K: Mammographic findings following reduction mammoplasty. Aesthetic Plast Surg 2001, 25(4):283-285.

Die Jahresstatistik für die Zervix-Zytologie: Rückblick und Ausblick nach der Aktualisierung der Münchner Nomenklatur

Katrin Marquardt

  1. Vereinbarung von Qualitätssicherungsmaßnahmen zur zytologischen Untersuchung von Abstrichen der Cervix uteri. Aktualisierte Fassung. Dtsch Aerztebl 2014; 33-34 A: 1434-5
  2. Marquardt K, Kolankowska I, Pfandzelter R: Jahresstatistik Zervix-Zytologie. Frauenarzt 2015; 56: 954-6
  3. Griesser H, Marquardt K, Jordan B, et al.: Münchner Nomenklatur III. Frauenarzt 2013; 11: 2-7
  4. Stubbe M, Mann E, Radtke A: Zytologisches Zervixkarzinom-Screening – Kontinuität und Wandel. Frauenarzt 2014; 55: 868-72
  5. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH, Wilkinson EJ, Zaino RJ, Wilbur D for members of the LAST Project Work Groups: The Lower Anogenital Squamous Terminology. Standardization Project for HPV-Associated Lesions: Background and Consensus Recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012; 136: 1266–97
  6. Stoler M, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM: The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status. Am J Surg Pathol 2015; 39: 729-36
  7. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL: Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 91: 430–4
  8. Baum ME, Rader JS, Gibb RK, McAlister RP, Powell MA, Mutch DG, Gao F, Wright JD.: Colposcopic accuracy of obstetrics and gynecologic residents. Gynecol Oncol 2006; 103: 966–70
  9. Gage JC et al. for the ASCUS LSIL Triage Study (ALTS) Group: Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 100: 264–72
  10. Mangold BR, Nauth HF. Konisation oder kolposkopisch gesteuerte Portiobiopsie? Vergleich der Wertigkeit der beiden Verfahren bei zytologischem Verdacht auf CIN III. Frauenarzt 2008; 49: 522-7
  11. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM: The accuracy of colposcopic biopsy: analysis from the placebo arm of the gardasil clinical trials. Int J Cancer 2011; 128: 1354–62
  12. Underwood M, Arbyn M, Parry-Smith W, De Bellis-Ayres S, Todd R, Redman CW, Moss EL. Accuracy of colposcopy-directed punch biopsies: a systematic review and meta-analysis. BJOG. 2012 Oct;119(11): 1293-301
  13. Griesser H, Marquardt K, Jordan B, et al.: Das Prozedere bei auffälligen Befunden. Kommentar zur Münchner Nomenklatur III. Frauenarzt 2015; 56: 10-3
  14. Nayar R, Wilbur DC: The Bethesda System for Reporting Cervical Cytology. Third Edition. Springer New York 2014
  15. Marquardt K, Griesser H: Jahresstatistik zytologischer Befunde erstmals nach der Münchner Nomenklatur III. Frauenarzt 2015; 56: 108-10
  16. Hilal Z, Tempfer C, Schiermeier S, Reinecke J, Ruppenkamp C: Progression oder Regression? – Stärken und Schwächen der neuen Münchner Nomenklatur III für die Zervix-Zytologie. Geburtsh Frauenheilk 2015; 75: 1-7
  17. Marquardt K, Griesser H: Münchner Nomenklatur III für die gynäkologische Zytodiagnostik der Zervix – zur Anwendung in der Praxis.gyn 2014; 5 (Beilage)

Innovative Verfahren in der Strahlentherapie bei Mammakarzinom: Bestrahlung in tiefer Inspiration

Stefanie Corradini

  1. Jemal, A., et al., Global Cancer Statistics. Ca-a Cancer Journal for Clinicians, 2011. 61(2): p. 69-90.
  2. Krebs in Deutschland 2007/2008. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Berlin 2012. 8. Ausgabe.
  3. Sautter-Bihl, M.L., et al., DEGRO practical guidelines for radiotherapy of breast cancer I. Strahlentherapie Und Onkologie, 2007. 183(12): p. 661-666.
  4. EBCTCG, Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet, 2000. 355(9217): p. 1757-1770.
  5. Abe, O., et al., Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005. 366(9503): p. 2087-2106.
  6. Van de Steene, J., G. Soete, and G. Storme, Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiotherapy and Oncology, 2000. 55(3): p. 263-272.
  7. Van de Steene, J., et al., Adjuvant radiotherapy for breast cancer: effects of longer follow-up. Radiotherapy and Oncology, 2004. 72(1): p. 35-43.
  8. Bartelink, H., et al., Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New England Journal of Medicine, 2001. 345(19): p. 1378-1387.
  9. de Bock, G.H., et al., Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies. European Journal of Cancer, 2006. 42(3): p. 351-356.
  10. Muren, L.P., et al., Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology, 2002. 62(2): p. 173-183.
  11. Whelan, T.J., et al., Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. Journal of Clinical Oncology, 2000. 18(6): p. 1220-1229.
  12. Preston, D.L., et al., Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res, 2003. 160(4): p. 381-407.
  13. Schultz-Hector, S. and K.R. Trott, Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys, 2007. 67(1): p. 10-8.
  14. Duma, M.N., M. Molls, and K.R. Trott, From heart to heart for breast cancer patients - cardiovascular toxicities in breast cancer radiotherapy. Strahlenther Onkol, 2014. 190(1): p. 5-7.
  15. Darby, S.C., Epidemiology of Radiotherapy induced cardiac damage. Radiotherapy and Oncology, 2011. 98(2): p. Pages S 11–S 12.
  16. Nilsson, G., et al., Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol, 2012. 30(4): p. 380-6.
  17. Cutter, D.J., S.C. Darby, and S.W. Yusuf, Risks of Heart Disease after Radiotherapy. Texas Heart Institute Journal, 2011. 38(3): p. 257-258.
  18. Taylor, C.W., et al., Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. International Journal of Radiation Oncology Biology Physics, 2007. 69(5): p. 1484-1495.
  19. Correa, C.R., et al., Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. Journal of Clinical Oncology, 2007. 25(21): p. 3031-3037.
  20. Marks, L.B., et al., The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys, 2005. 63(1): p. 214-23.
  21. Seddon, B., et al., Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol, 2002. 64(1): p. 53-63.
  22. Prosnitz, R.G., et al., Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer, 2007. 110(8): p. 1840-50.
  23. Darby, S.C., et al., Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncology, 2005. 6(8): p. 557-565.
  24. Jensen, B.V., Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Seminars in Oncology, 2006. 33(3): p. S15-S21.
  25. Offersen, B., I. Hojris, and M. Overgaard, Radiation-induced heart morbidity after adjuvant radiotherapy of early breast cancer - Is it still an issue? Radiotherapy and Oncology, 2011. 100(2): p. 157-159.
  26. Tanguturi, S.K., et al., Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Pract Radiat Oncol, 2015. 5(6): p. 358-65.
  27. Smyth, L.M., et al., The cardiac dose-sparing benefits of deep inspiration breath-hold in left breast irradiation: a systematic review. Journal of Medical Radiation Sciences, 2015. 62(1): p. 66-73.

Für immer müde? Fatigue bei Krebspatienten: Erscheinungsformen, Ursachen, Behandlung

Susanne Ditz

  1. Alexander S, Minton O, Stone PC (2009) Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors Journal of clinical oncology. Official journal of the American Society of Clinical Oncology 27(8):1197–1201.
  2. Baumann F T, Schüle K (Hrsg.) (2008) Bewegungstherapie und Sport bei Krebs. Köln: Deutscher Ärzteverlag. S. 274.
  3. Cella D F (1998) Quality of life. In: Holland J (Hrsg.) Psycho-Oncology. New York: Oxford University Press S. 1135–1146.
  4. Cella D F (1998a) Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology 25 (suppl. 7):43–46.
  5. Cella D F, Davis K, Breitbart W, Curt G, Fatigue Coalition (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 15;19(14):3385–3391.
  6. Cramp F, Daniel J (2009) Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2.
  7. Deutsche Krebsgesellschaft (Hrsg.) Sport und Krebs. Kann man dem Krebs davonlaufen? FORUM, Band 26, Ausgabe 03.2011.Kim S H, Park B W, Ahn S H, 
  8. Goedendorp M M, Gielissen M F M, Verhagen C A H H V M, Bleijenberg G (2009) Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database of Systematic Reviews 1.
  9. Heim M, Weis J (2014). Fatigue bei Krebserkrankung. Schattauer Stuttgart 205 S
  10. Holmes M D, Chen W Y, Feskanich D, Kroenke C H, Graham A, Colditz M D (2005) Activity and Survival After Breast Cancer Diagnosis. JAMA 293:2479–2486.
  11. Horneber M, Fischer I, Dimeo F, Rüffer JU; Weis J (2012): Cancer-related fatigue: epidemiology, pathogenesis, diagnosis and treatment Dtsch Arztebl 109(9):161-72
  12. Lundstrom S H, Furst C J (2006) The use of corticosteroids in Swedish palliative care. Acta Oncologica 45:430–437.
  13. Minton O, Stone P C (2008) How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast cancer Res Treat 112:5–13.
  14. Minton O, Stone P C (2009) Systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Annals of Oncology 20(1):17–25.
  15. National Comprehensive Cancer Network (2008) Cancer-related Fatigue-Guidelines. V.I. www.nccn.org.
  16. Noh D Y, Nam S J, Lee ES Yun Y H (2006) Prevalence and correlates of fatigue and depression in breast cancer survivors: Breast cancer quality care study. Journal of Clinical Oncology 24 (18S):683.
  17. Piper B F, Lindsey A M, Dodd M J (1987) Fatigue mechanisms in cancer patients: Developing nursing theory. Oncology Nursing Forum 14(6):17–23.
  18. Rank M, Freiberger V, Schoenberg MH (2012): Sporttherapie bei Krebserkrankungen. Schattauer Stuttgart 180 S
  19. Razon M, Dreisbach A, Lertora J J L et al. (2002) Palliative uses of methylphenidate in patients with cancer: A review. J Clin Oncol 20:335–339.
  20. Siegmund-Schultze N (2009) Onkologie: „Sport ist so wichtig wie ein Krebsmedikament“. Dtsch Arztebl 106(10): A-444.
  21. Singer S, Kuhnt S, Zwerenz R et al. (2011): Age-and sex- standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. Br J Cancer 105:445-51
  22. Whitehead L (2009) The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manage 37(1):107–128.
  23. Wolin K Y, Yan Y, Colditz G, Lee I-M (2009) Physical Activity and Colon Cancer Prevention: A Meta-analysis. British Journal of Cancer 100:611–616.
  24. Yates P, Aranda S, Hargraves M, Mirolo B, Clavarino A, McLachlan SA, Skerman H (2005) Randomized Controlled Trial of an Educational Intervention for Managing Fatigue in Women Receiving Adjuvant Chemotherapy for Early-Stage Breast Cancer. Journal of Clinical Oncology 23 (25):6027–6036.

Aktuelles zur endokrinen Therapie des metastasierten Mammakarzinoms in der Postmenopause

Eva-Maria Grischke, Florin-Andrei Taran, Stefan Kommoss, Andreas Hartkopf, Sara Brucker

  1. AGO-Leitlinien unter wwwago-online.de – Leitlinienprogramm Mammakarzinom 2 / 2015.
  2. Nabholtz et al., J Clin Oncol 2000; 18: 3758–3767 
  3. Bonneterre et al., J Clin Oncol 2000; 18: 3748–3757 
  4. Mouridsen et al., J Clin Oncol 2001; 19: 2596–2606
  5. Paridaens et al., Proc Am Soc Clin Oncol, 2004
  6. Mouridsen et al., JCO 2003; Vol. 21, No 11; pp. 2101–2109 
  7. Paridaens et al., EJC; Vol. 2, No. 3, p 126/EBCC 3/2004
  8. Gradishar WJ et al SABCS 2006 , Poster 12 
  9. Bedard PL, et al. Breast Cancer Res Treat. 2008; 108 (3): 307–317 
  10. Normanno N, et al., Endocr relat Cancer 2005; 12(4): 721–747 
  11. Pink JJ et al. Br J Cancer 1996; 74(8): 1227–1236 
  12. Xu et al., J Cancer Res Clin Oncol 2011; 137: 1005–1013 
  13. Rimawi & Osborne. Nat Rev Clin Oncol 2012; 9: 133–134 
  14. Johnston SR, et al. CCR. 2010;16(7):1979-1987
  15. Miller TW, et al. J Clin Invest. 2010;120(7):2406–2413.
  16. Beck T, et al. Breast Cancer Res Treat. 2014; 143: 459–467 
  17. Campone M, et al., Poster-Präsentation SG-BCC 2013; St. Gallen, Schweiz. 
  18. Yardley DA, et al. Adv Ther. 2013; 30: 870–884; 2 
  19. Baselga J, et al. N Engl J Med. 2012; 366: 520–529. 4. Fachinformation Afinitor, März 2015 
  20. Fasching, P., et al., Breast Cancer Treatment with Everolimus and Exemestane for ER+ Women – Ergebnisse der dritten Interminsanalyse der nicht-interventionellen Studie BRAWO. Vortrag anlässlich der 35. Jahrestagung der Deutschen Gesellschaft für Senologie (DGS). 
  21. Finn RS, et al. AACR 2013. 
  22. ZhangY et al  AACR, NCI EORTC 2011  
  23. Turner, C., et al. N Engl J Med. 2015; 373: 209–219
  24. Tolaney, S., et al. Clinical activity of abemaciclib, an oral cell cycle inhibitor in metastatic breast cancer. San Antonio Breast Cancer Symposium, December 9–13, 2014, Abstract #763 
  25. Maira SM, et al., Mol Cancer Ther 2012; 11: 317–28;2
  26. Fritsch CM et al. Cancer Res. 2012;72: Abstract 3748;4